Next Article in Journal
Integration of miRNA and mRNA Co-Expression Reveals Potential Regulatory Roles of miRNAs in Developmental and Immunological Processes in Calf Ileum during Early Growth
Next Article in Special Issue
Roles for the IKK-Related Kinases TBK1 and IKKε in Cancer
Previous Article in Journal
Challenges of Decoding Transcription Factor Dynamics in Terms of Gene Regulation
Previous Article in Special Issue
NF-κB, Mesenchymal Differentiation and Glioblastoma
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessFeature PaperReview
Cells 2018, 7(9), 133; https://doi.org/10.3390/cells7090133

NFKB1 and Cancer: Friend or Foe?

Newcastle Fibrosis Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, Tyne and Wear NE2 4HH, UK
*
Author to whom correspondence should be addressed.
Received: 15 August 2018 / Revised: 30 August 2018 / Accepted: 4 September 2018 / Published: 7 September 2018
(This article belongs to the Special Issue NF-κB in Cancer)
Full-Text   |   PDF [972 KB, uploaded 12 September 2018]   |  

Abstract

Current evidence strongly suggests that aberrant activation of the NF-κB signalling pathway is associated with carcinogenesis. A number of key cellular processes are governed by the effectors of this pathway, including immune responses and apoptosis, both crucial in the development of cancer. Therefore, it is not surprising that dysregulated and chronic NF-κB signalling can have a profound impact on cellular homeostasis. Here we discuss NFKB1 (p105/p50), one of the five subunits of NF-κB, widely implicated in carcinogenesis, in some cases driving cancer progression and in others acting as a tumour-suppressor. The complexity of the role of this subunit lies in the multiple dimeric combination possibilities as well as the different interacting co-factors, which dictate whether gene transcription is activated or repressed, in a cell and organ-specific manner. This review highlights the multiple roles of NFKB1 in the development and progression of different cancers, and the considerations to make when attempting to manipulate NF-κB as a potential cancer therapy. View Full-Text
Keywords: NF-κB; NFKB1; p105/p50; Bcl-3; cancer; inflammation; apoptosis NF-κB; NFKB1; p105/p50; Bcl-3; cancer; inflammation; apoptosis
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Concetti, J.; Wilson, C.L. NFKB1 and Cancer: Friend or Foe? Cells 2018, 7, 133.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top